Pieris Pharmaceuticals (NASDAQ:PIRS – Get Free Report) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Tuesday.
Pieris Pharmaceuticals Stock Up 1.0 %
PIRS stock traded up $0.15 during trading hours on Tuesday, hitting $15.59. The company’s stock had a trading volume of 46,391 shares, compared to its average volume of 47,970. The stock has a 50 day moving average price of $16.57 and a two-hundred day moving average price of $13.83. Pieris Pharmaceuticals has a 12 month low of $6.20 and a 12 month high of $22.32. The company has a market capitalization of $20.58 million, a PE ratio of -1.29 and a beta of 0.66.
Institutional Trading of Pieris Pharmaceuticals
A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. Frazier Life Sciences Management L.P. bought a new position in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 15,942 shares of the biotechnology company’s stock, valued at approximately $267,000. Frazier Life Sciences Management L.P. owned about 1.21% of Pieris Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 40.11% of the stock is currently owned by hedge funds and other institutional investors.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.
Recommended Stories
- Five stocks we like better than Pieris Pharmaceuticals
- What is a Special Dividend?
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- Basic Materials Stocks Investing
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
